InMed Pharmaceuticals (IN) News Today → The only financial event in 2024 that matters (From Porter & Company) (Ad) Free IN Stock Alerts Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14, 2024 | msn.comINM Stock Earnings: InMed Pharmaceuticals Reported Results for Q3 2024April 6, 2024 | theglobeandmail.comInMed Pharmaceuticals (NASDAQ: INM) Releases Favorable Results from INM-901 Preclinical AD StudiesFebruary 13, 2024 | finanznachrichten.deInMed Pharmaceuticals: InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business UpdateFebruary 13, 2024 | finance.yahoo.comInMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business UpdateJanuary 22, 2024 | theglobeandmail.comInMed Pharmaceuticals (NASDAQ: INM) CEO to Present at January Water Tower Research Fireside ChatJanuary 16, 2024 | finance.yahoo.comInMed Pharmaceuticals Provides Business Update and Milestones for 2024December 12, 2023 | finance.yahoo.comInMed’s (NASDAQ: INM) Latest Research Demonstrates Potential In Treating Alzheimer’s with a Rare Cannabinoid AnalogNovember 30, 2023 | theglobeandmail.comInMed Pharmaceuticals (NASDAQ: INM) Advancing INM-089 to Target Treatment of Age-Related Macular DegenerationNovember 29, 2023 | finance.yahoo.comInMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular DegenerationNovember 14, 2023 | msn.comInMed Pharmaceuticals GAAP EPS of -$0.76, revenue of $901.8MOctober 24, 2023 | finance.yahoo.comInMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept StudiesOctober 13, 2023 | benzinga.comCannabis Industry Report Highlights Positive Sentiment and Growth Potential at Benzinga ConferenceAugust 11, 2023 | finanznachrichten.deDelveInsight Business Research, LLP: Epidermolysis Bullosa Market to Surge at a CAGR of ~8% During the Study Period (2019-2032), Predicts DelveInsightJuly 20, 2023 | finance.yahoo.comInMed Provides Update on BayMedica Rare Cannabinoid BusinessJuly 7, 2023 | msn.comGame-Changer In Epidermolysis Bullosa Treatment? Cannabis Compound Holds PromiseApril 25, 2023 | marketwatch.comBiosynthesis of Cannabinoids Market Growth By 2030April 20, 2023 | marketwatch.comBlepharitis-Pipeline Market Description and Business Overview By 2030March 27, 2023 | benzinga.comInMed Pharmaceuticals: Pushing Pharma Forward With Rare CannabinoidsMarch 17, 2023 | benzinga.comDespite Global Economic Pressures, InMed Pharma's Accomplishments In 2022 Could Be A Catalyst For Further Growth In 2023March 13, 2023 | finance.yahoo.comInMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin ConditionsFebruary 21, 2023 | benzinga.comInMed Pharmaceuticals Q2 FY23 Revenue Grows 77% YoY, What About Net Loss?February 20, 2023 | marketwatch.comEpidermolysis Bullosa Market is Booming in Near Future 2023-2028 with Top Countries DataFebruary 20, 2023 | finanznachrichten.deInMed Pharmaceuticals Inc.: InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business UpdateFebruary 17, 2023 | msn.comInMed Pharmaceuticals GAAP EPS of -$0.91, revenue of $0.47MFebruary 17, 2023 | yahoo.comInMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business UpdateFebruary 10, 2023 | finance.yahoo.comInMed Submits Form 12b-25January 24, 2023 | marketwatch.comGlobal Blepharitis-Pipeline Market Size Growth Rate Analysis 2023 by Market Overview, Segments, Regions, Market Share and Forecast to 2028January 4, 2023 | marketwatch.comThinking about buying stock in Geron Corp, InMed Pharmaceuticals, Kingsoft Cloud, Vivos Therapeutics, or Baozun?December 14, 2022 | marketwatch.comSpasticity Treatment Market Research Highlighting Global Opportunities 2023 | Growth Trends and Share Forecast to 2029December 12, 2022 | nz.finance.yahoo.comInMed Announces Appointment of Interim Chief Financial Officer and Change of AuditorNovember 23, 2022 | msn.comBiotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory UpdateNovember 17, 2022 | finance.yahoo.comInMed (INM) Gets Grant to Begin Neurodegenerative Diseases ProgramNovember 16, 2022 | msn.comWhy Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day SessionNovember 16, 2022 | benzinga.comThinking about buying stock in Fast Radius, Camber Energy, InMed Pharmaceuticals, Taiwan Semiconductor, or Exela Technologies?November 16, 2022 | msn.comInMed stock rockets after research grant awarded for cannabinoid analogs to treat Alzheimer's, Parkinson'sNovember 12, 2022 | finanznachrichten.deInMed Pharmaceuticals Inc.: InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business UpdateNovember 12, 2022 | benzinga.comInMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business UpdateSeptember 30, 2022 | marketwatch.comInMed Pharmaceuticals Shares Rise 30% on Higher-Than-Normal VolumeSeptember 9, 2022 | nasdaq.comInMed Pharma Gains 9%August 25, 2022 | marketwatch.comInMed Pharma to Consolidate SharesAugust 25, 2022 | uk.investing.comHere's Why InMed Pharmaceuticals Shares Are Getting Hammered TodayAugust 25, 2022 | seekingalpha.comInMed Pharmaceuticals sinks 16% over consolidating 1 for 25 shares to meet listing requirementsJuly 25, 2022 | finance.yahoo.comInMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis BullosaJuly 18, 2022 | markets.businessinsider.comInMed Pharma Names Michael Woudenberg As COOJune 14, 2022 | finance.yahoo.comInMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin ConditionsJune 9, 2022 | finance.yahoo.comInMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness SectorMay 4, 2022 | finanznachrichten.deEdison Investment Research Limited: InMed Pharmaceuticals : Notable Launches of High-Value Rare CannabinoidsApril 21, 2022 | baystreet.caThis is Why Investors Are Excited About the Potential of Rare CannabinoidsMarch 17, 2022 | benzinga.comInMed Launching Additional Rare Cannabinoids In Response To DemandMarch 17, 2022 | seekingalpha.comInMed CFO steps down, interim CFO appointed Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IN and its competitors with MarketBeat's FREE daily newsletter. Email Address Warren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector… (Ad)Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market… Click here for the details IN Media Mentions By Week IN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IN News Sentiment▼0.000.76▲Average Medical News Sentiment IN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IN Articles This Week▼00▲IN Articles Average Week Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: HLS News Today RX News Today DB News Today CWEB News Today LABS News Today MPH News Today NDVA News Today WLLW News Today VPH News Today CTX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:IN) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.